SYMPOSIA - JERUSALEM, SUNDAY, SEPTEMBER 17, 2000
 – ICC – Jerusalem International Convention Center

 

Hall A

Hall B/C

Hall D

Hall E

Hall F

Hall G

Hall H

09:00-12:30
Restoring early insulin secretion in type 2 diabetes prevents mealtime glucose spikes

Novartis Pharma AG

09:00-12:30

Progression of type 2 diabetes – inevitable or preventable?

SmithKline Beecham Pharmaceuticals

09:00-12:30

Measurement of Ketone Bodies

Abbott GmbH Diagnostika

09:00-12:30

After UKPDS – Achieving New Goals in Glycaemic Control

Merck Lipha s.a.

09:00-12:30

The European Diabetes Epidemiology Study Group (Edeg) Symposium

09:00-11:30

Achieving Treatment Goals in the Management of Diabetes

Pfizer Inc./Aventis Pharma

  

14:00-17:30

The Critical Link Between Hypertension and Diabetes: Evidence Based Medicine and Emerging Options

Bristol-Myers Squibb/Sanofi-Synthelabo

14:00-17:30

Type 2 Diabetes – Treatment at the Crossroads

Bayer AG

14:00-17:00

Introducing Apligrafâ : The First Tissue-Engineered Human Skin Equivalent Proven to Heal Diabetic Foot Ulcers

Novartis Pharma

14:00-17:30

Improving Survival in Type 2 Diabetes – New Strategies

Merck Lipha s.a.

14:00-17:30

Diabetes Technology Advances in Clinical Care: Continuous Glucose Monitoring System and Continuous Subcutaneous Insulin Infusion

MiniMed Inc.

14:00-17:30

Sexual Dysfunction and the Diabetic Patient

Pfizer Pharmaceuticals Israel, Ltd.

15:00-17:30

St. Vincent (SVD) Working Group on Evidence Based Medicine in Diabetes

  

JERUSALEM, SUNDAY, SEPTEMBER 17, 2000
 – JERUSALEM HOTELS

Crowne Plaza Hotel Ballroom

Crowne Plaza Hotel

Arad Hall

Crowne Plaza Hotel

Ein Gedi Hall

Jerusalem Hilton Hotel

Renaissance Hotel Ballroom

Renaissance Hotel Queen of Sheba

Laromme Hotel

Four Points Sheraton Hotel

09:00-12:30

New Analogue Advances in Glycaemic Control – Introducing NovoRapidâ

Novo Nordisk A/S

09:00-12:30

Cochrane Metabolic and Endocrine Disorders Group Annual Meeting

09:00-12:30

Founding Meeting of the Dietician Group for the Study and Implementation of Nutrition Education in Diabetes

09:00-11:45

Innovations in Managing Diabetes Through the Lifecycle

Insulin Resistance: Today and Tomorrow

Eli Lilly and Company

12:30-14:00

The Benefits of Aggressive Blood Pressure Control in the Multiple Risk Patient

Pfizer Inc.

  

  

  

13:15-17:10

Innovations in Managing Diabetes Through the Lifecycle

B. Decade of Experience with Humalog: Realizing the Advantages of a Rapid Acting Insulin Eli Lilly and Company

14:30-16:30

The Rationale for Aggressive Therapy for Diabetic Dyslipidemia

Pfizer Inc.

14:00-16:00

The Future of Diabetes Care

New PPAR modulators: advancing the shape of clinical practice

Glaxo Wellcome plc

14:00-17:30

Management strategies refined: The emerging role of thiazolidinediones in type 2 diabetes

Takeda Chemical Industries, Ltd. Japan

14:00-17:30

Intensive Diabetes Care in the 21st Century

Disetronic Medical Systems AG

      

SATURDAY, SEPTEMBER 16, 2000
16:00-22:00 Registration and Distribution of Material

SUNDAY, SEPTEMBER 17, 2000

08:00-19:00 Registration continues

09:00-17:00 Symposia organized on the Occasion of the 36th Annual Meeting of the EASD

20:00 Official Opening Ceremony including a concert performed by the Jerusalem Symphony Orchestra sponsored by Bayer AG,
followed by Get Together Reception (at the Sultan's Pool at the foot of the Old City Wall)

MONDAY, SEPTEMBER 18, 2000

TUESDAY, SEPTEMBER 19, 2000

09:00-10:00
A.M. Cohen Lecture: "The Negev Desert, Migration, Islands and Diabesity: Genes and Environment Clashing" – Paul Zimmet, Australia Hall A

09:00-10:00

Camillo Golgi Lecture: "From Hyperglycaemia to the Dysregulation of Vascular Remodelling in Diabetes" – U. di Mario, Italy Hall A

10:00-10:30 COFFEE BREAK AND EXHIBITION VISIT

10:00-10:30 COFFEE BREAK AND EXHIBITION VISIT

Hall A

Hall B

Hall CP

Hall C

Hall E

Hall G

Hall D

Hall A

Hall B

Hall CP

Hall C

Hall E

Hall G

Hall D

10:30-12:30

Cardio-vascular Morbidity and Mortality

10:30-12:30

Nutrition and Diet

10:30-12:30

Hypo-glycaemia

10:30-12:30

Genetics of Type 1 Diabetes

10:30-12:30

Glucose Transport

10:30-12:30

Mechanisms of Insulin Secretion: Ion Channels & Exocytosis

10:30-12:30

Gene Poly-morphisms

 

10:30-12:00

Nephropathy: Patho-physiology

10:30-12:00

Epidem-iology of Diabetes

10:30-12:00

Trans-plantation

10:30-12:00

GLP-1

10:30-12:00

Obesity

10:30-12:00

Mechanisms of Endothelial Damage

10:30-12:00

Functional Studies Using Transgenic Animals

12:45-14:45 LUNCH BREAK, POSTER AND EXHIBITION VISIT

Poster Event A (12:45-13:45) and B (13:45-14:45)

12:15-14:15 LUNCH BREAK, POSTER AND EXHIBITION VISIT

Poster Event C (12:15-13:15) and D (13:15-14:15)

15:00-16:30

Diabetic Foot

15:00-16:30

Clinical Hetero-geneity of Diabetes

15:00-16:30

Diabetes in Pregnancy: Pathophysio-logical Aspects

15:00-16:30

Clinical Immunology

15:00-16:30

Signalling Pathways in Vascular Disease

15:00-16:30

Regulation of Gene Expresssion in Beta-Cells

15:00-16:30

Regulation of Insulin Sensitivity

14:30-16:00

Diabetic Nephropathy: Treatment

14:30-16:00

FFA and Lipids in the Patho-genesis of Diabetic Vasculopathy

14:30-16:00

New Data on Sulfony-lurea

14:30-16:00

Patho-genesis of Type 1 Diabetes: Experimental Immunology

14:30-16:00

Metabolic Changes in Obesity

14:30-16:00

Substrate Metabolism and Insulin Secretion

14:30-16:00

Insulin Signalling I

16:30-17:00 COFFEE BREAK AND EXHIBITION VISIT

16:00-16:30 COFFEE BREAK AND EXHIBITION VISIT

17:00-18:15

State of the Art Symposium:

Thiazolidinedions – Metabolic Actions and Side Effects

17:00-18:00

State of the Art Lecture:

The Missing Link: A Unifiying Biochemical Mechanism for Diabetic Compli-cations

17:00-18:00

State of the Art Lecture:

Clinical Implications of a Continuous Glucose Monitoring System

17:00-18:00

State of the Art Lecture:

Genetic Lessons from Animal Models of Diabetes

17:00-18:00

State of the Art Lecture:

Evidence-based Medicine & Diabetes: The Cochrane Review Group Movement

 

 

16:30-17:10

State of the Art Lecture:

Clinical Perspectives of Long-acting Insulin Analogues

16:30-18:30

State of the Art Symposium:

IGT – A Pre-diabetic Condition

16:30-18:30

Joint Presentation of EASD Study Groups on Neuropathy, Nephro-pathy, Eye Compli-cation, Diabetic Foot

16:30-18:30

EASD Diabetes

Education Study Group (DESG) Presentation

16:30-18:30

State of the Art Symposium:

(Micro)

vascular Dysfunction in Insulin Resistance/

Prediabetes

16:30-18:30

EASD/JDFI State of the Art Symposium:

Primary Non-graft Function in Pancreas and Islet Transplant-ation

 

16:30-18:30

State of the Art Symposium:

Mitogenic versus Metabolic Effects of Insulin and IGF-1

Evening: Visit and Reception at the Israel Museum (Group A)

20:30 Chamber Music Concert – Jerusalem Trio in the Jerusalem Theatre - $20 p/p

21:00: Anaphase – Batsheva Dance Company (at the ICC) - $30 p/p

     

WEDNESDAY, SEPTEMBER 20, 2000

THURSDAY, SEPTEMBER 21, 2000

Hall A

Hall B

Hall CP

Hall C

Hall E

Hall G

Hall D

Hall A

Hall B

Hall CP

Hall C

Hall E

Hall G

Hall D

09:00-10:00

Clinical Update: Managing Patients with Hyper-tension

09:00-10:00

Clinical Update:

Prolonging Beta-Cell Rest (Honeymoon Period)

09:00-10:00

State of the Art Lecture: The Making of a Beta-Cell

09:00-10:00

State of the Art Lecture: Insulin Resistance and Human Disease: Rationale for Assessment and Method-ological Approaches

09:00-10:00

State of the Art Lecture: The Offspring of the Diabetic Mother – Diabetes Begets Diabetes

 

09:00-10:00

State of the Art Lecture: Stone-Age Thrifty Genes and the Profligate Society

 

 

09:00-10:00

State of the Art Lecture: After HUGO What's Next in Mapping Genes for Type 2 Diabetes?

09:00-10:00

State of the Art Lecture: The Global Rise of Type 2 Diabetes in Adolescents – An Emerging Problem

09:00-10:00

State of the Art Lecture: New Insights in the Patho-genesis of Diabetic Kidney Disease

09:00-10:00

State of the Art Lecture: Peptide Therapy of Type 1 Diabetes

09:00-10:00

State of the Art Lecture: Assessing Energy Balance

   

10:00-10:30 COFFEE BREAK AND EXHIBITION VISIT

10:00-10:30 COFFEE BREAK AND EXHIBITION VISIT

10:30-12:30

New Treatments for Type 1 Diabetes

 

10:30-12:30

Neuropathy

10:30-12:30

Genetics of Type 2 Diabetes

10:30-12:30

Advanced Glycation Endproducts and Endothelial Dysfunction in Vivo

10:30-12:30

Outcome of the Diabetic Pregnancy

10:30-12:30

Gene Expression in ß-Cell Growth and Phenotype

10:30-12:30

Insulin Resistance

10:30-12:00

Insulin Sensitizers

10:30-12:00

Pathogenic Principles in Microangiopathy

10:30-12:00

Cost Effectiveness and Quality Management

10:30-12:00

Prediction/
Prevention of Type 2 diabetes

10:30-12:00

Oxidative Stress and Coagulation

10:30-12:00

ß-Cell Dysfunction and Damage in Type 1 Diabetes Mellitus

10:30-12:00

Lipid Metabolism

12:45-14:45 LUNCH BREAK, POSTER AND EXHIBITION VISIT

Poster Event E (12:45-13:45) and F (13:45-14:45)

12:15-13:15

Claude Bernard Lecture: “On the Track to the Beta-Cell” – W. Malaisse, Belgium Hall A

15:00-16:00

Treatment

15:00-16:00

Silent Heart

15:00-16:00

Pancreas

15:00-16:00

Prediction of

15:00-16:00

Beta-Cell

15:00-16:00

Retinopathy

15:00-16:00

Cellular

13:15

Closing Ceremony followed by a Farewell Party

Strategies in Type 2 Diabetes

Disease

Transplantation

Type 1 Diabetes

Dysfunction and Damage in Type 2 Diabetes Mellitus

 

 

Stress and Insulin Action

  

16:00-16:30 COFFEE BREAK AND EXHIBITION VISIT

   

16:30-17:30

Minkowski Lecture: “Factors Controlling Beta-Cell Identity and Glucose Homeostasis” – H. Edlund, Sweden Hall A

    

17:30-18:30 36th EASD General Assembly Hall A

   

Evening: Visit and reception at the Israel Museum (Group B)